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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and lethal malignancy. Publically
available cell lines are mostly of lingual origin, or have not been carefully characterized. Detailed characterization of
novel HNSCC cell lines is needed in order to provide researchers a concrete keystone on which to build their
investigations.
Methods: The USC-HN1 cell line was established from a primary maxillary HNSCC biopsy explant in tissue culture.
The immortalized cells were then further characterized by heterotransplantation in Nude mice;
immunohistochemical staining for relevant HNSCC biomarkers; flow cytometry for surface markers; cytogenetic
karyotypic analysis; human papillomavirus and Epstein-Barr virus screening; qRT-PCR for oncogene and cytokine
analysis; investigation of activated, cleaved Notch1 levels; and detailed 35,000 gene microarray analysis.
Results: Characterization experiments confirmed the human HNSCC origin of USC-HN1, including a phenotype
similar to the original tumor. Viral screening revealed no HPV or EBV infection, while western blotting displayed
significant upregulation of activated, cleaved Notch1.
Conclusions: USC-HN1, a novel immortalized cell line has been derived from a maxillary HNSCC. Characterization
studies have shown that the cell line is of HNSCC origin and displays many of the same markers previously
reported in the literature. USC-HN1 is available for public research and will further the investigation of HNSCC and
the development of new therapeutic modalities.
Background
Head and neck squamous cell carcinoma (HNSCC)
represents a cancer of increasing incidence worldwide
with more than 45,000 head and neck malignancies
diagnosed each year, of which greater than 90% are of
squamous cell origin. This particularly lethal cancer, the
sixth most common world-wide, has not seen an
improvement in overall survival in more than four dec-
ades [1,2]. Standard-of-care treatment for the disease
has been limited to surgical resection or combination
chemotherapy and radiation therapy. Despite these
treatments, the high rates of primary-site recurrence
and common metastases to loco-regional lymph nodes
are responsible for the dismal prognosis of HNSCC.
Clinically, more than one half of patients with loco-
regional advanced disease treated with chemoradiation,
surgery or both experience recurrence within two years
[3-5]. The presence of lymph node metastases alone
decreases the chances of long-term survival by 50% [4].
Bio-molecular research into the cause of HNSCC has
had some success; however, without the ongoing devel-
opment of newly-established HNSCC cell lines,
researchers are limited in these pursuits. At the present
time, most of the currently available HNSCC cell lines
deposited at the American Type Tissue Collection
(ATCC) are derived from lingual tumors [1] despite
the fact that there are multiple anatomically-exclusive
locations from which HNSCC can develop. As shown in
Figure 1, HNSCC tumors can arise from any location of
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any medium, provided the original work is properly cited.the upper aerodigestive tract, including the nasal cavity,
sinus cavities, oral cavity, pharynx, or larynx. The var-
ious locations associated with malignant transformation
implore the need for a wide-ranging database of tumor
cell lines representative of all of the anatomic locations.
Secondly, distinct biomodels of HNSCC have been
established based on the viral infectivity and carcino-
genic exposure of the patient. By establishing cell lines
representative of the entire upper aerodigestive tract, a
comprehensive database would be available to elucidate
the development and progression of HNSCC. Moreover,
these types of studies could lead to the discovery and
advancement of targeted therapies that might alter the
clinical outcome of these tumors.
Current research has delineated many generalized and
specific markers to characterize HNSCC cell lines. Histo-
logically, HNSCC is a squamous epithelial carcinoma
with variable degrees of keratinization. Well-differen-
tiated cell lines may display keratin pearls, whereas
poorly differentiated, anaplastic cell lines may have little-
to-no keratin production. HNSCC is typically character-
ized by a malignant phenotype including large, pleo-
morphic nuclei and large or multiple nucleoli;
cytoplasmic vacuolation with abundant cytoplasm; inter-
cellular bridging; and high numbers of mitotic figures,
both typical and atypical. Beside these morphologic fea-
tures, surface and intracellular markers are also used to
identify the cell line lineage. Along with traditional mar-
kers such as FABP5, epidermal growth factor receptor,
E-cadherin, CD74, and CD24, newly published biomar-
kers for the staining of HNSCC primary tumor biopsies
include IL13Ra2, CD44v6, and the stem cell marker
CD133 [6]. The population of cancer stem cells (CSC)
within the tumor biopsy represented by CD44
+CD133
+
cells has been shown to have a high incidence of metasta-
sis and invasion. These cells, however, have been found
to be a rare subset of cells (2-10%) in the overall tumor
cell population [7,8]. Karyotypic analysis of HNSCC typi-
cally reveals an aberrant chromosome set with various
deletions, translocations, and double chromosomes,
including a deletion of the small arm of chromosome 3
found in many epithelial cancers [9]. Human papilloma
virus (HPV), specifically HPV subtype-16 is associated
with HNSCC in about 30% of cases and is most com-
monly associated with tumors arising from the orophar-
ynx. HPV-positive HNSCC is now considered a distinct
biomodel from HPV-negative HNSCC, occurring in
patients without the usual history of alcohol and/or
tobacco use [10]. Epstein-Barr virus (EBV) is a com-
monly-associated Herpes virus linked with nasopharyn-
geal carcinoma not found in HNSCC. Bergmann et al.[ 3 ]
have reported extensive evidence of the immunomodula-
tory effects of HNSCC, including the local and regional
suppression of the immune system by interleukins, TGF-
b, and other cytokines. Oncogenes such as c-myc,a n dc-
Kit and mutations in tumor suppressor genes p53 and Rb
are also characteristically found in HNSCC [4,11-13].
Lastly, it has been reported that Notch1,a n
Figure 1 Schematic of the upper aerodigestive tract and locations of various head and neck malignancies.
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entiation, may play a role in the oncogenesis of multiple
types of cancers including leukemias, lung, melanoma,
breast, and neurological tumors [14] but its role in
HNSCC has not been studied extensively to date.
In this report, we now describe the establishment and
characterization of a unique HNSCC cell line designated
U S C - H N 1 .T h ec e l ll i n ew a sd e r i v e df r o ma ni n v a s i v e
primary right superior alveolar ridge squamous cell car-
cinoma in a nonsmoking patient (Stage IVa, T4aN0M0,
based on the American Joint Commission on Cancer
Staging, 6
th Ed.) and has been found to recapitulate the
phenotype of the original tumor biopsy. Heterotrans-
plantation and cytogenetic studies demonstrate its onco-
genic derivation and monoclonality, respectively. This
cell line has been made available for others in the scien-
tific community through the American Tissue-type Cell
Collection (ATCC, http://www.atcc.org) and represents
an important model for further studies of HNSCC.
Methods
Cell Lines and Cells
HeLa, HUT102, Raji, FaDu, and SW579 cell lines were
obtained from the ATCC. All cell lines were maintained
in complete medium in humidified incubators at 37°C
with 5% CO2. IRB approval from the USC Keck School
of Medicine (HS-09-00048) has been obtained for the
collection and use of HNSCC tumor biopsies. Tumor
biopsies were surgically resected and placed into 50 mL
collection tubes containing approximately 30 mL of
RPMI-1640 medium with 20% FCS, 1% Antibiotic-Anti-
mycotic Solution (Mediatech, Inc., Manassas, VA), 10
u g / m lC i p r o f l o x a c i n - H C l( M e diatech, Inc.), and 10 ug/
ml Gentamicin Sulfate (Irvine Scientific, Santa Ana,
CA). The tubes were immediately put on ice and trans-
ported to the laboratory for tissue dissociation.
Establishment of Cell Line USC-HN1
Tumor biopsies were mechanically dissociated into small
tissue fragments using scissors and forceps. Fragments
were then further dissociated enzymatically in 20 ml of
RPMI-1640 medium containing 10% FCS, and 0.2 micron
membrane filtered 0.01% hyaluronidase, 0.1% collage-
nase, and 0.01% DNase (Sigma Chemical Co., St. Louis,
MO) for 40 min in a 37°C water bath with intermittent
mixing. After digestion, the cells and fragments were
washed once in complete medium (RPMI-1640 medium
containing 20% FCS, 1% Antibiotic-Antimycotic Solution,
10 ug/ml ciprofloxacin HCl, and 10 μg/ml Gentamicin
Sulfate), treated for 30 seconds in 30 ml sterile filtered
RBC lysis buffer (8.3 g NH4Cl, 1 g KHCO3, and 0.037 g
EDTA/L dH2O), washed again in complete medium, and
seeded in two T-75 flasks. After 2-3 days of incubation in
a humidified 5% CO2 37°C incubator, the fragments were
repeatedly pipetted with a 2 ml glass pipette for further
dissociation. After centrifugation, the cells and residual
small fragments were resuspended in freezing medium
(RPMI-1640 medium with 30% FCS, 1% Penicillin/
S t r e p t o m y c i n ,a n d1 0 %D M S O ) ,a l i q u o t e di n t of o u r - s i x
1.8 ml cryotubes (Nunc, Denmark), and placed in liquid
nitrogen for long-term storage.
Cells and fragments that adhered to the T-75 flasks
were grown in complete medium for 2 weeks before
being trypsinized and passaged weekly to new flasks.
When the malignant cells were seen to grow, the nor-
mal fibroblastic cells were removed by differential trypsi-
nization to enrich the malignant cell population. Finally,
malignant cells were cloned in petri dishes using cloning
r i n g st oi s o l a t eap u r ep o p u l a t i o no fH N S C Cc e l l st o
establish the cell line. The doubling time was deter-
mined by cell count measurements at 24 hr intervals for
one week from cells in culture after trypsinization. After
establishment of the cell line, interval screening for
Mycoplasma was performed using the MycoAlert Myco-
plasma Detection Kit (Lonza, Rockland, ME).
Heterotransplantation in Nude mice
Six-week-old female Nude mice were purchased from
Harlan Sprague Dawley (Indianapolis, IN). Institutional
Animal Care and Use Committee-approved protocols
and institutional guidelines for the proper humane care
and use of animals in research were followed. Mice (n =
5) were injected s.c. in the flank with a 0.2 mL inoculum
of 5 × 10
6 viable USC-HN1 cells. Three weeks after
implantation, tumors were removed and the tissue was
e i t h e rf l a s hf r o z e ni nl i q u i dn i t r o g e no rf i x e di n1 0 %
neutral buffered formalin overnight at room temperature
for paraffin-embedded procedures.
Immunohistochemistry
For immunohistochemistry (IHC) studies, cytospin pre-
parations of USC-HN1 cells and tissue sections of USC-
HN1 tumors grown in Nude mice were used and com-
pared to stained, fixed slides of the original tumor.
USC-HN1 cells grown for 24 hr directly on sterile
printed 25 × 75 mm glass slides (Bellco Glass, Inc.,
Vineland, NJ) were fixed sequentially with 2% parafol-
maldehyde (Polysciences, Inc., Warrington, PA) for
10 min at room temperature and acetone for 5 min at
-20°C. For tissue sections, excised heterotransplanted
USC-HN1 tumors from Nude mice were fixed overnight
in 10% neutral buffered formalin and embedded in par-
affin blocks. For cell culture and tissue morphology stu-
dies, Wright-Giemsa and hematoxilin & eosin stains
were used, respectively on air-dried cytospin prepara-
tions. In addition, USC-HN1 cytospin preparations and
5 micron tissue sections were stained with monoclonal
antibodies against human CD44 (clone DF1485 Dako
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trogen, Carlsbad, CA), epidermal growth factor receptor
(EGFr) (clone E30 Biogenex, San Ramon, CA), keratin
(clone AE1/AE-3 Covance, Berkeley, CA), p53 (clone
1801 CalBiochem, San Diego, CA), and Rb (clone
RbG3-245 BD Biosciences, San Diego, CA). Observation,
evaluation and image acquisition were made using Leica
DM2500 microscope (Leica Microsystems, http://www.
leica-microsystems.com) connected to an automated,
digital SPOT RTke camera and SPOT Advanced Soft-
ware (SPOT Diagnostic Instrument Inc., http://www.
diaginc.com). Images were further resized and brigh-
tened for publication using Adobe Photoshop software
(Adobe, http://www.adobe.com).
Flow cytometry
Single cell suspensions (1 × 10
6 cells in 100 μl) in FACS
buffer (1% FCS in PBS) were stained with FITC, PE,
PerCPCy5.5, and APC conjugated antibodies. For intracel-
lular staining, cell surface staining was performed first, fol-
lowed by buffer fixation/permeabilization (eBioscience,
San Diego, CA) and intracellular staining. Antibodies used
w e r e :C D 2 4( M L 5 ) ,C D 7 4( M - B741), E-cadherin (36/E-
cadherin) (BD Biosciences); IL-13Ra (B-D13), c-Kit
(104D2) (Santa Cruz Biotechnology, Santa Cruz, CA);
CD44v6 (VFF-7) (Abcam, Cambridge, MA); CD133
(TMP4) (eBioscience); FABP5 (311215) (R&D Systems,
Minneapolis, MN); and anti-human Epidermal Growth
Factor Receptor (CTL-R2) (Cancer Therapeutics Labora-
tories, Inc., Los Angeles, CA). Staining with isotype con-
trols antibodies (eBioscience) was performed in parallel,
and all samples were done in duplicate. Samples were run
on a FACS Calibur flow cytometer (BD) and data acquisi-
tion and analysis were performed using Cell Quest Pro
software (BD) at the USC Flow Cytometry core facility.
Cytogenetics
Karyotype analysis was performed by the Division of
Anatomic Pathology, City of Hope (Duarte, CA) using
cultured USC-HN1 cells.
Polymerase chain reaction (PCR) viral screen
G e n o m i cD N Aw a si s o l a t e df r o mU S C - H N 1 ,H e L a ,
HUT102, Raji, FaDu, and SW579 cells using TRIrea-
gent (Sigma) per manufacturer’s instructions. For PCR,
50-100 ng of DNA was amplified with specified pri-
mers (300 nM final concentration) using REDTaq
ReadyMix PCR Master Mix (Sigma) in a 25 μl reaction
and run on an iCycler (BioRad, Hercules, CA). HPV
infectivity was screened using previously reported con-
sensus primers MY09/MY11 (expected product ~450
bp) and GP5+/GP6+ (expected product ~150 bp)
[15,16]. Consensus primers for the EBV gene EBNA2
(expected product ~600 bp) was used to screen for the
presence of EBV as previously reported [17].
Cytokine and oncogene analysis by qRT-PCR
T o t a lR N Aw a si s o l a t e df r o mU S C - H N 1a n dF a D u
human pharyngeal carcinoma cell lines by RNeasy
Mini Kit (Qiagen, Valencia, CA) per manufacturer’s
instructions. RNA was DNase treated using Turbo
DNase (Applied Biosciences, Foster City, CA) per man-
ufacturer’s instructions. For qRT-PCR, 100-200 ng of
DNase-treated RNA was amplified with Power SYBR
Green RNA-to-CT 1-Step Kit (Applied Biosciences).
Primer sequences for cytokines and oncogenes were
from the NIH qRT-PCR database [[18], http://primer-
depot.nci.nih.gov] and were synthesized by the USC
Core Facility (Table 1). Specific markers analyzed
included p53, Rb, c-myc, c-Kit,V E G F - A ,V E G F - C ,
Cox2, TGFb1, TGFb2, IL-1b,I L - 4 ,I L - 6 ,I L - 8 ,a n d
Table 1 Cytokine and Oncogene Primers for qRT-PCR
Target Forward Primer Reverse Primer
p53 5’ - GCTCGACGCTAGGATCTGAC - 5’ 5’ - CAGGTAGCTGCTGGGCTC - 3’
Rb 5’ - GTTGGTCCTTCTCGGTCCTT - 3’ 5’ - CAAAGCAGAAGGCAACTTGA - 3’
c-myc 5’ - CTCCTCCTCGTCGCAGTAGA - 3’ 5’ - GCTGCTTAGACGCTGGATTT - 3’
c-Kit 5’ - GCCCACGCGGACTATTAAGT - 3’ 5’ - CTGGGATTTTCTCTGCGTTC - 3’
VEGF-A 5’ - CACACAGGATGGCTTGAAGA - 3’ 5’ - AGGGCAGAATCATCACGAAG - 3’
VEGF-C 5’ - CTCCAGATCTTTGCTTGCAT - 3’ 5’ - CTGTGGCGTGTTCTCTGCT - 3’
COX2 5’ - TTCAAATGAGATTGTGGGAAAATTGCT - 3’ 5’ - AGATCATCTCTGCCTGAGTATCTT - 3’
TGFb-1 5’ - GCAGAAGTTGGCATGGTAGC - 3’ 5’ - CCCTGGACACCAACTATTGC - 3’
TGFb-2 5’ - CTCCATTGCTGAGACGTCAA - 3’ 5’ - CGACGAAGAGTACTACGCCA - 3’
IL-1b 5’ - GGAGATTCGTAGCTGGATGC - 3’ 5’ - GAGCTCGCCAGTGAAATGAT - 3’
IL-4 5’ - AGCGAGTGTCCTTCTCATGG - 3’ 5’ - CAGCCTCACAGAGCAGAAGA - 3’
IL-6 5’ - CATTTGTGGTTGGGTCAGG - 3’ 5’ - AGTGAGGAACAAGCCAGAGC - 3’
IL-8 5’ - AGCACTCCTTGGCAAAACTG - 3’ 5’ - CAAGAGCCAGGAAGAAACCA - 3’
IL-10 5’ - GCCACCCTGATGTCTCAGTT - 3’ 5’ - GTGGAGCAGGTGAAGAATGC - 3’
GAPDH 5’ - CTCTGCTCCTCCTGTTCGAC - 3’ 5’ - TTAAAAGCAGCCCTGGTGAC - 3’
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gene Mx3000P cycler with MxP QPCR software (Stra-
t e g e n e ,L aJ o l l a ,C A ) .G e n e - s p e c i f i ca m p l i f i c a t i o nw a s
normalized to GAPDH and fold change in gene
expression calculated relative to Universal Human
Reference RNA (Stratagene). For statistical analysis,
the student’s t-test for independent samples was used
with a significance level a =0 . 0 5t oc o m p a r eg e n e
expression between samples. Statistical tests were per-
formed using GraphPad Prism software (La Jolla, CA).
Western blot for activated Notch1
For western blots, 50 μg of protein from sonicated
whole cell lysates were fractionated in a 10% Tris-gly-
cine polyacrylamide gel, electrotransferred to PDVF
membranes, and probed overnight with primary anti-
body for activated Notch1 (clone Val1744) (Cell Signal-
ing, Danvers, MA). Blots were stripped and reprobed for
GAPDH (clone FL-335) (Santa Cruz Biotech), to nor-
malize the amount of sample loaded. Horseradish perox-
idase-conjugated secondary antibodies (Caltag,
Burlingame, CA) were then applied, followed by signal
detection using Immobilon Western Chemiluminescent
HRP Substrate (Millipore, Billerica, MA).
Microarray gene expression profiling
Total RNA from USC-HN1 was collected and analyzed
by microarray as previously described [6]. Briefly, 5 μg
of total RNA was reverse-transcribed using 5’-amino-
modified primers with amino-allyl-dUTP. cDNA synthe-
sized from USC-HN1 cells was labeled with Cy5 dye,
and cDNA from universal RNA (uRNA) labelled with
Cy3 dye. Labeled and combined cDNA probes were
denatured, mixed in SlideHyb #1 hybridization buffer
(Ambion, Austin, TX), and placed onto microarray
s l i d e s .T h i r t yf i v et h o u s a n d oligonucleotide arrays were
hybridized at 42°C in MAUI hybridization system (Bio-
Micro Systems) for overnight, washed with 1 × SSC
with 0.05% SDS and 0.1 × SSC buffers, and then were
quickly spin-dried. Microarray slides were scanned on a
GenePix 4000B scanner (Axon Instruments, Inc., Foster
City, CA) with a 5 μm resolution. Scanned raw images
were analyzed and data files were generated with Gene-
Pix Pro 5.1 (Axon) software. For analysis, data files were
uploaded into mAdb (microarray database), and ana-
lyzed by the software tools provided by the Center for
Information Technology (CIT), NIH. A standard global
normalization approach was used for each experiment.
All of the extracted data was normalized using a 50
th
percentile (median) normalization method. Statistical
analyses and t-test were performed to identify differen-
tially expressed genes.
Results
Case report of patient NR with Invasive Right
Maxillary SCC
Patient NR is a 57-year-old Hispanic female with a past
medical history of hypothyroidism and dyslipidemia. Of
note, she does not have a family history of head and
neck cancer nor does she have a history of tobacco or
alcohol use. In February, 2009 she presented to her pri-
mary care physician with a three-month history of fati-
gue, weight loss, right-sided facial pain, oral ulcers,
loose teeth, and bleeding gingiva. A right anterior maxil-
lary gingival biopsy subsequently revealed a well-differ-
entiated squamous cell carcinoma. A series of CTs,
including the sinuses and neck, were performed which
showed an extensive mass of the right hard and soft
palates extending into the right maxillary sinus with sig-
nificant bone destruction without noted nodal metas-
tases (Stage IVa, T4aN0M0). In May, 2009 the patient
underwent a complex resection and reconstruction pro-
cedure including a complete right maxillectomy and
ethmoidectomy with a split-thickness skin graft repair.
Intraoperative frozen section margins of the maxillary
crest, pterygoid plates, palate, ethmoid air cells, and
buccal cavity were all clear and free of tumor. Final
pathological diagnosis of the resected right maxilla indi-
cated an invasive, well-differentiated squamous cell car-
cinoma, keratinizing type with perineural invasion
(Figure 2).
Establishment of the USC-HN1 cell line
A cell line, designated USC-HN1, was established from the
primary tumor biopsy specimen after approximately 4
weeks in culture. Initially, explants were seen attaching to
the flask and tumor cells grew centrifugally from these
small tissue fragments (Figure 3). By ten days the explants
were trypsinized and re-plated as single cells along with
growing stromal cells. At this time, explants were grown
only in Pen/Strep antibiotic solution (Gibco, Carlsbad,
CA) and were not affected by the early use of anti-mycotic
or other antibacterial reagents that were added to the early
cultures. By 3 weeks, tumor cells were seen rounding up
and growing throughout the T-75 flask amongst the nor-
mal stromal fibroblasts that grew in parallel. Differential
trypsinization was used to remove the majority of the
fibroblasts which detached sooner than the tumor cells.
To isolate a pure population of tumor cells, 100 detached
cells were plated in 100 mm petri dishes and colonies
were removed by trypsinization using cloning rings. These
isolated colonies were used to establish the cell line which
typically grows rapidly forming tight monolayers in flasks.
The cells are easily detached with pre-warmed 0.05% tryp-
sin/EDTA (Gibco) and were found to have a rapid
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that other head and neck squamous cell lines have dou-
bling times between 17-240 hrs with a median time of
26.5 hr [1]. In culture, the USC-HN1 cell line has numer-
ous mitotic figures, is tightly adherent, and demonstrates
typical squamous cell morphology (Figure 4A) that has
remained constant since the establishment of the cell line.
Wright-Giemsa staining of cell-cultured slide preparations
shows malignant cells with large nucleoli, some cytoplas-
mic vacuoles, and an abundance of cytoplasm typical of
squamous cells (Figure 4B). Mycoplasma testing on multi-
ple passages was found to be negative.
Heterotransplantation into Nude mice
Cultured USC-HN1 cells were heterotransplanted subcu-
taneously in Nude mice to produce expanding tumors in
5/5 mice that displayed the cell line’s malignancy (Figure
5). At 3 weeks, the tumors were excised. Histologic sec-
tions of the heterotransplanted tumor stained with hema-
toxilin and eosin show a poorly differentiated squamous
cell carcinoma arranged as a sheet with areas of tumor
necrosis and bluntly infiltrative borders. The tumor cells
are tightly cohesive featuring from moderate to abundant
eosinophilic cytoplasm. The nuclear to cytoplasmic ratio is
markedly increased with nuclei showing frequent,
Figure 3 Morphologic appearance of early tumor explants from HNSCC biopsy samples. Phase-contrast photomicrograph of tumor
explants isolated from HNSCC biopsies in culture after 2-4 weeks with cells growing directly from the explants in a monolayer (A ×100, B ×200
original magnification).
Figure 2 Hematoxilin and eosin stained histologic sections from the original tumor. An invasive well-differentiated squamous cell
carcinoma, the tumor is arranged as cohesive islands of cells showing nuclear pleomorphism with occasionally prominent nucleoli. Mitotic
activity is present including atypical forms. In areas, abundant keratin production is present including whirling “keratin pearl” configurations.
Intercellular bridges are visible at high power magnification. Surrounding the invasive tumor, a dense lymphoplasmacytic inflammatory infiltrate
is present (A ×200, B ×400 original magnification).
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atypical forms such as ring and tripolar configurations.
Intercellular bridges are focally present but faint.
Immunophenotype of USC-HN1 in cell culture and in situ
Immunophenotypic characterization of USC-HN1 cells in
c u l t u r ea n df r o mt u m o r sg r o w ni nN u d em i c ed e m o n -
strated similarity to the original tumor and confirmed a
keratinizing squamous cell carcinoma (Figure 6). USC-
HN1 cells demonstrate strong, uniform nuclear p53 and
Rb expression, as well as positive expression of keratin, E-
cadherin, EGFr, and CD44 in situ consistent with HNSCC
as well as the original tumor biopsy [4,7,13,19]. There is
decreased staining of E-cadherin and CD44 in situ com-
pared with cultured cells. Conversely, EGFr staining is
stronger in those cells grown as heterotransplants. CD44
Figure 4 Establishment of the USC-HN1 cell line. (A) Phase contrast microphotograph of growing USC-HN1 cells showing numerous mitotic
cells (rounded, luminescent cells) with a tightly, adherent squamous cell morphology. (B) Cytology of the USC-HN1 cell line shows malignant
cells with large nuclei and nucleoli and an abundance of cytoplasm typical of squamous cells (Cytospin, Wright-Giemsa stain, ×100 original
magnification).
Figure 5 Heterotransplantation of USC-HN1 cell line into Nude mice. (A) Appearance of subcutaneous USC-HN1 tumor in Nude mouse. (B
and C) Low and high magnification of USC-HN1 Nude mouse heterotransplant showing a poorly differentiated squamous cell carcinoma
arranged as a sheet with areas of tumor necrosis and bluntly infiltrative borders. The tumor cells are tightly cohesive featuring from moderate to
abundant eosinophilic cytoplasm. The nuclear to cytoplasmic ratio is markedly increased with nuclei showing frequent, prominent nucleoli.
Mitotic activity is abundant including atypical forms such as ring and tripolar configurations. Intercellular bridges are focally present but faint
(H&E ×200 and ×400 original magnification).
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in comparison with the original tumor biopsy.
USC-HN1 characterization by flow cytometry
The phenotype of USC-HN1 cell line was further char-
acterized by surface and intracellular staining for com-
mon HNSCC biomarkers by fluorescently-labeled
monoclonal antibodies and analysis by flow cytometry
(Table 2). Compared to isotype controls, USC-HN1 dis-
plays significantly increased staining of FABP5, E-cad-
herin, and CD24. EGFr, c-Kit, and CD74 staining also
showed an increased mean fluorescence intensity,
whereas IL-13Ra,C D 4 4 v 6a n dC D 1 3 3d i dn o ts h o wa
significant increase.
Cytogenetic analysis
Cytogenetic analysis of the USC-HN1 cell line was per-
formed in collaboration with the City of Hope (Duarte,
CA) (Figure 7). All mitotic cells analyzed from the USC-
HN1 cell line were clonally abnormal. The complex near-
triploid clone was characterized by a modal number of
chromosomes of 71 and by deletions involving chromo-
s o m e sX ,3 ,4 ,6 ,a n d7 ,a d d i t i o n a lm a t e r i a lo fu n k n o w n
origin on chromosomes 8, 13, 17, and 19, a derivative
chromosome 6 resulting from an unbalanced translocation
with the long arm of chromosome 14, gains of chromo-
somes X, 7, 11, 15, and 19, losses of chromosomes 9, 14,
18, 21, and 22, as well as gain of a large marker chromo-
some and a small suspected ring chromosome.
PCR Viral screen for HPV and EBV
Since HPV and EBV are associated with malignancies of
the head and neck, the USC-HN1 cell line was screened
for these oncogenic viruses by PCR using consensus pri-
mers for HPV L1 and EBV EBNA2 genes as described pre-
viously [15,17]. The results showed that the USC-HN1 did
not have specific amplifications for either the HPV L1
sequence or for the EBV sequence (Figure 8). HeLa cells
Figure 6 Immunoperoxidase staining of USC-HN1 cells in Nude mouse heterotransplant and in cytospin preparations for HNSCC
classification markers. Photomicrograph of immunoperoxidase staining of original tumor biopsy (top), IHC stained formalin-fixed paraffin-
embedded tissue sections of USC-HN1 Nude mouse heterotransplant (middle), and USC-HN1 cells from culture in a cytospin preparation
(bottom) for keratin, E-cadherin, EGFr, CD44, p53 and Rb (×200 original magnification).
Table 2 Analysis of USC-HN1 cytokines and surface
markers by FACS.
% Positive MFI
Target Isotype Control Antibody Isotype Control Antibody
FABP5 0.01 97.49 31.80 1310.47 ***
E-cadherin 0.01 49.74 6.87 203.69 ***
CD24 0.01 7.87 6.87 90.52 ***
EGFR 4.50 10.71 37.70 198.78 **
c-Kit 0.01 0.26 6.55 14.01 **
CD74 0.01 0.15 6.87 9.16 **
IL-13Ra 5.47 2.63 8.89 7.89 *
CD44v6 0.06 0.04 13.27 9.38 *
CD133 7.57 3.02 38.84 20.67 *
*** > 1000% Control MFI
** 100-1000% Control MFI
* < 100% Control MFI
USC-HN1 cells in culture were stained for HNSCC-related cytokines and
surface markers (left column) using monoclonal antibodies and analyzed by
flow cytometry. Samples were run in duplicate. Percent of positive staining
cells (middle columns) and mean fluorescence intensity (right columns) is
shown for each antibody target and its isotype control.
Liebertz et al. Head & Neck Oncology 2010, 2:5
http://www.headandneckoncology.org/content/2/1/5
Page 8 of 14(known HPV-positive cervical carcinoma) and SW579
(known HPV-negative thyro i dc a r c i n o m a )w e r er u ni n
parallel as controls for both HPV consensus primer sets
(MY09/MY11 and GP5+/GP6+). For the EBV screen, EBV
+ Raji and EBV
- T-cell lymphoma TLBR-1 cell lines
[17,20] were run in parallel as controls.
Cytokine and oncogenes expression
The cell line was also tested by qRT-PCR for its expres-
sion levels of pertinent oncogenes and cytokines. Run in
parallel with RNA extracted from the human pharyngeal
carcinoma FaDu cell line and compared to Universal
Human Reference RNA, the overall expression levels of
USC-HN1 closely paralleled that of FaDu, a documented
HNSCC cell line (Table 3). Statistical analysis revealed
significant differences between the expression levels of
c-myc,V E G F a ,T G F - b1, and IL-1b produced by USC-
HN1 and the FaDu cell line, and no significant differ-
ences between p53, Rb, c-Kit,V E G F c ,C O X 2 ,T G F - b2,
IL-4, IL-6, IL-8, and IL-10.
Figure 7 Karyotype of USC-HN1. Karyotype of USC-HN1 cell line showing a near-triploid clone (modal 71) demonstrating features characteristic
of head and neck cancer including multiple deletions (chromosomes X, 3, 4, 6, and 7), isochromosome formation, and many breakpoints around
centromeres.
Figure 8 PCR studies for the presence of oncogeneic viruses. (A) HPV detection using consensus primers GP5
+/GP6
+ (1a-4a) and MY09/
MY11 (1b-4b) demonstrating USC-HN1 (3a, 3b) is negative for HPV infection. Positive (HeLa 4a, 4b), negative (SW579 2a, 2b), and water (1a, 1b)
controls were run in parallel. (B) PCR study for detection of EBV with consensus primer showing USC-HN1 negative (3). Positive (Raji, 2), negative
(HUT102, 4), and water (1) controls were run in parallel.
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Notch1 protein levels were determined by Western blot
for the USC-HN1 cell line in comparison to expression
levels seen in positive (Karpas 299) and negative (Siha)
cell line controls. Based upon these studies, USC-HN1
demonstrated an increased level of activated Notch1
protein at levels equal to or higher than the Karpas 299
positive control (Figure 9).
Microarray gene expression profiling
Microarray gene expression analysis was performed on
isolated total RNA from USC-HN1 cells and compared
to the results previously reported in HNSCC tumor
biopsy samples [6]. To compare the similarities of gene
expression profile between the USC-HN1 cells and
HNSCC tumor biopsy samples, we focused on the up-
regulated genes in USC-HN1 cells. A total of 328 genes
with p < 0.05 and log2 fold ≥ 1 in USC-HN1 cells com-
pared with previous results from normal tonsils were
identified. Many up-regulated genes identified in USC-
HN1 cells were also present in HNSCC biopsies (Table
4). These common genes were classified into various
categories of biological functions including those related
to immune response such as MIF and CD24, which
were currently identified in HNSCC [6]. Other signa-
tures of up-regulated genes in USC-HN1 cells include
ATP5H, HSP27, FABP5, E-cadherin, EIF4G2, KRT18
and KRT8, RPLP0 and RPS18, which are associated with
various biological processes such as cell growth and
maintenance, cell cycle regulation, metabolism, and pro-
tein translation and synthesis (Table 4).
Discussion
We describe the clinical presentation of an invasive
well-differentiated maxillary HNSCC and the establish-
ment of the USC-HN1 cell line from the primary tumor
biopsy. Of note, patient NR was a non-smoker and did
not receive preoperative radiotherapy or chemotherapy.
Her tumor was consistent with a diagnosis of primary
H N S C Co np r e s e n t a t i o nb yt i s s u eh i s t o l o g ya n di m m u -
nostaining for HNSCC markers. The USC-HN1 cell line
was established in culture approximately 4 weeks after
seeding by isolation from co-existing fibroblastic mono-
layers which grew from the explanted cultures. USC-
HN1 shares many characteristics with the primary
tumor and has a phenotype typical of an advanced
HNSCC. The doubling time of the cell line is extremely
rapid (18 hr) compared to other human tumor cell lines
from HNSCC [1] or those from other tumor types.
Table 3 Oncogene and cytokine analysis of HNSCC cell
lines by qRT-PCR.
USC-HN1 FaDu
Gene Average Fold Δ Average Fold Δ t-test
p53 0.2111 0.3671 0.5377
Rb 1.1222 0.5076 0.2022
c-myc 0.9730 0.5848 0.0025
c-Kit 0.0006 0.0002 0.0286
VEGFa 0.4272 0.1406 0.0026
VEGFc 0.2402 0.1450 0.7093
COX2 0.0385 0.0064 0.4963
TGF-B1 1.1887 0.1312 0.0205
TGF-B2 0.0261 0.0172 0.2514
IL-1B 0.2091 29.4400 0.0064
IL-4 0.3472 0.0767 0.0660
IL-6 0.0661 0.0905 0.1403
IL-8 0.1866 0.1293 0.1389
IL-10 0.0204 0.0078 0.3217
RNA was extracted from USC-HN1 and FaDu cell lines, treated with DNase,
and analyzed against Universal Human Reference RNA. Gene amplification
was normalized to GAPDH. Analysis of oncogenes and cytokines depict an
overall similar profile for both USC-HN1 and FaDu. C-myc, c-Kit, VEGFa, and
TGF-B1 are significantly upregulated in USC-HN1 compared to FaDu; IL-1B was
significantly down-regulated.
Figure 9 Western Blot: Notch1. Western blot analysis of the active, cleaved portion of Notch1 run in parallel with confirmatory GAPDH. (lane A)
Karpas 299 positive control; (lane B) Siha low expression control; and (lane C) USC-HN1 shows high expression levels of Notch1 protein.
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Page 10 of 14Table 4 Selected up-regulated genes identified in USC-HN1 cells by microarray analysis also present in HNSCC
tumor biopsies.*
GeneBank Access ID Gene Symbol & Annotation Log2 Fold Difference**
Immune Response
L19686 MIF, macrophage migration inhibitory factor 3.1
NM_002116 HLA-A, major histocompatibility complex, class I A 2.2
X16302 IGFBP2, insulin-like growth factor binding protein 2 1.7
L33930 CD24, CD24 antigen 1.1
Cell Growth, Maintenance/Cell cycle Regulation
M26326 KRT18, keratin 18 6.2
NM_002273 KRT8, keratin 8 5.8
X95404 CFL1, cofilin 1 4.1
NM_005022 PFN1, profilin 1 4.0
Y00503 KRT19, keratin 19 3.6
AL031670 FTL, ferritin, light polypeptide 3.2
AF026291 CCT4, chaperonin subunit 4 3.2
NM_004360 CDH1, E-cadherin 2.3
Translation and Protein Synthesis
AK001313 RPLP0, ribosomal protein LP0 6.3
L11566 RPL18, ribosomal protein L18 5.5
M64241 RPL10, ribosomal protein L10 5.2
X69150 RPS18, ribosomal protein S18 4.9
U73824 EIF4G2, translation initiation factor 4 gamma 2 4.2
L06499 RPL37A, ribosomal protein L37A 4.0
M84711 RPS 3A, ribosomal protein S3A 3.8
U25789 RPL21, ribosomal protein L21 3.7
AL117412 EIF4A2, eukaryotic translation initiation factor 4A 2.9
Z21507 EEF1D, eukaryotic translation elongation factor 1D 1.2
Metabolism
M26252 PKM2, pyruvate kinase, muscle 5.7
NM_021130 PPIA, peptidylprolyl isomerase A (cyclophilin A) 4.7
X13794 LDHB, lactate dehydrogenase B 4.4
Z23090 HSPB1, heat shock 27 kDa protein 4.2
Y13936 PPM1G, protein phosphatase 1G 2.8
U09813 ATP5G3, ATP synthase H+ transporting subunit 2.7
AF061735 ATP5H, ATP synthase H+ transporting subunit 2.5
D29011 PSMB5, proteasome subunit, beta 5 2.4
Y00483 GPX1, glutathione peroxidase 1 2.3
M60483 PPP2CA, protein phosphatase 2 catalytic subunit 2.2
NM_001679 ATP1B3, ATP synthase Na+/K+ transporting, beta 3 1.6
M94856 FABP5, fat acid binding protein 5 1.2
Ion Binding Proteins
D38583 S100A11, S100 calcium binding protein A11 1.8
NM_020672 S100A14, S100 calcium binding protein A14 1.0
Others
S54005 TMSB10, thymosin, beta 10 4.2
M14328 ENO1, enolase 1 4.0
M26880 UBC, ubiquitin C 3.4
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was successfully heterotransplanted into Nude mice
where it was found to produce invasive tumors. In com-
parison to the original tumor, the heterotransplant most
prominently shows a higher nuclear to cytoplasmic
ratio, markedly increased mitotic activity, prominent
necrosis and less conspicuous intercellular bridging.
Marked keratinization is also absent. The difference
between the original tumor histology and the subse-
quently developed cell line’s heterotransplant is likely
due to the outgrowth of a more aggressive, less differen-
tiated cell sub-population during establishment of the
cell line in culture. In addition, sections of the hetero-
transplanted tumors stained for HNSCC markers were
mostly consistent with previously reported primary
tumor biopsies including strong EGFr, p53, and Rb
staining, as is seen in many epithelial malignancies [4].
Furthermore, fixed sections of the original tumor biopsy
and cytospin cell preparations were also stained for
these biomarkers. Noted differences of the cytospin pre-
parations relative to the heterotransplanted tumors were
a decrease in keratin and EFGr staining and an increase
in E-cadherin and CD44 positivity. The moderate stain-
ing of keratin found in the heterotransplant tumor sec-
tions is similar with the original tumor, described as a
keratinizing squamous cell carcinoma. The light staining
of E-cadherin in the heterotransplanted tumor may indi-
cate the malignant potential of the cells as they begin to
undergo epithelial-to-mesenchymal transition and con-
sequently lose cell-cell adhesive and interactive mole-
cules [12,19]. When the malignant cells are placed in a
murine host, they are subjected to a myriad of microen-
vironmental factors different from that of cell culture
medium or a human host. The loss of CD44 in the het-
erotransplanted tumor sections may be explained by the
presence of factors that increase the differentiation of
USC-HN1 in situ in contrast to its stem cell-like pheno-
type that predominates in cell culture or in vivo [8].
Analysis of the flow cytometry data supports a
comparable picture to the IHC in which almost all
USC-HN1 cells were positive for FABP5 and half were
E-cadherin positive (97.5% and 49.7%, respectively).
Furthermore, USC-HN1 showed a significant increase in
EGFr staining as is to be expected in an epithelial
malignancy [4]. Interestingly, stem cell markers were
not uniformly expressed in the sample of cultured
HNSCC although CD24 and CD74 showed increased
staining unlike CD133. USC-HN1 is grown in a serum-
containing medium, which may irreversibly differentiate
any stem cells in the population and therefore alter the
surface marker expression in the remaining pluripotent
cells [8]. Conversely, these cells may represent only a
subpopulation of tumor stem cells found previously to
display various combinations of CD24, CD74, and
CD133 [2]. Our results did not show a significant
amount of surface staining for the recently published
markers IL-13Ra or CD44v6. However, these published
studies were performed on primary tumor biopsies and
not on established cell lines [6]. The karyotype analysis
of USC-HN1 did show a highly abnormal chromosome
content consistent with other known HNSCC cell lines
and solid tumors. Aneusomy is a recurrent finding in
cytogenetically abnormal head and neck tumor speci-
mens [9]. Deletions are the most common structural
rearrangement observed, particularly involving the short
arms of chromosomes 3 and 8, as well as the short arm
regions of the acrocentric chromosomes. Many struc-
tural breakpoints in HNSCC involve centromeric or
pericentromeric regions of the chromosomes, often
resulting in isochromosome formation or derivative
whole-arm translocations involving the acrocentric chro-
mosomes [Personal communication with Dr. Joyce L.
Murata-Collins, Division of Anatomic Pathology, City of
Hope, Duarte, CA]. Most notably, the partial deletion of
chromosome 3 and the near-triploid karyotype of the
clonal population are consistent with the HNSCC-
derived nature of this cell line [9]. Viral oncogene inves-
tigation detected no infection with either HPV or EBV.
In this regard, 80-90% of nasopharyngeal carcinomas
have been shown to be infected with EBV but very few
(<1%) of HNSCC are positive. An extensive literature
report revealed only two cases of EBV
+ HNSCC and
both cases were co-infected with HPV [21,22]. The
EBV-negative characteristic of USC-HN1 further sup-
ports the origin of the tumor as a squamous and not a
nasopharyngeal carcinoma. By contrast, 30% of HNSCC
are infected with a subtype of HPV [12]. USC-HN1
represents a unique HPV-negative HNSCC cell line in
Table 4: Selected up-regulated genes identified in USC-HN1 cells by microarray analysis also present in HNSCC
tumor biopsies.* (Continued)
X67951 PRDX1, peroxiredoxin 1 3.2
M36981 NME2, non-metastatic cells 2 protein 3.1
NM_006016 CD164, CD164 antigen 2.6
*All selected genes with p-value < 0.05.
**Log2 ratio fold-differences between USC-HN1 cells and normal tonsil tissues were determined by subtracting the ratio of genes in normal tonsil tissue versus
uRNA from the ratio of genes in USC-HN1 cells versus uRNA. (Log2 ratio of 1 equals to 2-fold difference between USC-HN1 cells and normal tissue; Log2 ratio of
2 equals to 4-fold difference between USC-HN1 and normal tissue, and so on).
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tobacco or drink alcohol and does not have a family his-
tory of head and neck malignancies.
Further characterization of the USC-HN1 cell line
revealed a similar pattern of cytokine and chemokine
expression compared to the pharyngeal carcinoma
FaDu, a widely used HNSCC cell line. As previously
reported HNSCC are highly immunomodulatory and
alter their tumor microenvironment by the production
of various cytokines [3]. The production of VEGFc has
been correlated with increased metastatic potential in
HNSCC [23], and USC-HN1 has shown a statistically
increased production of VEGFc compared with FaDu.
Importantly, with the exception of c-myc, the USC-HN1
cell line reveals statistically equivalent expression of
proto-oncogenes and tumor-suppressor genes as FaDu
and a cytokine expression profile different from FaDu,
which will offer researchers yet another biomodel to
study the microenvironment of HNSCC. Finally, the
increased levels of activated, cleaved Notch1 found in
USC-HN1 are indicative of its malignant potential, and
although published reports imply various levels of
Notch1 activity among HNSCC cell lines [24], it may
serve as a future avenue for a new therapeutic approach
since multiple trials of Notch1 inhibitors are in progress
in patients with other tumor types [14].
Microarray analysis of USC-HN1 revealed a pattern
of gene expression similar to HNSCC tumor samples
previously reported [6]. In addition, specific up-regu-
lated genes including CD24, E-cadherin, FABP5, kera-
tins, heat shock protein (27 kDa), and others identified
by microarray analysis were also identified by flow
cytometry and immunostaining. These results support
the origin of the cell line and further confirm the
pathology as HNSCC.
Conclusions
In conclusion, we have established a novel HPV-negative
HNSCC cell line from a non-smoking elderly patient.
USC-HN1, one of only a few cell lines derived from the
upper alveolar ridge, recapitulates the primary tumor’s
malignant behavior. It also displays surface and intracy-
toplasmic biomarkers consistent with HNSCC. This cell
line will provide researchers with a well-delineated
model to investigate the oncogenesis of HNSCC and
may provide a source of material to develop new thera-
peutic reagents capable of treating these deep-seated
and highly resistant tumors.
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